The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 15, 2015, Pages 2331-2341

  Munir, Kashif M ^a   Davis, Stephen N ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

dipeptidyl peptidase inhibitor; glucagon like peptide 1 agonist; metformin; sodium glucose co transporter 2 inhibitor; type 1 diabetes; glucosidase inhibitor

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; BIGUANIDE DERIVATIVE; DACLIZUMAB; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; PRAMLINTIDE; ROSIGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; VILDAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

AUTOIMMUNITY; BLOOD GLUCOSE MONITORING; BODY WEIGHT; DISEASE DURATION; DRUG APPROVAL; DRUG EFFICACY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; REVIEW; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; METABOLISM;

BIGUANIDES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES;

EID: 84942198689     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1084502     Document Type: Review

References (66)

1. Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013;13(6):795-804
2. Rankin D, Cooke DD, Heller S, et al. Experiences of using blood glucose targets when following an intensive insulin regimen: A qualitative longitudinal investigation involving patients with Type 1 diabetes. Diabet Med 2012;29(8):1079-84
3. Abdelghaffar S, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 2009(1):CD006691
4. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002;18(3):192-200
5. Goke B, Herrmann-Rinke C. The evolving role of alpha-glucosidase inhibitors. Diabetes Metab Rev 1998;14(Suppl 1):S31-8
6. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005(2):CD003639
7. Dimitriadis G, Karaiskos C, Raptis S. Effects of prolonged (6 months) alphaglucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metab Res 1986;18(4):253-5
8. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care 1997;20(3):248-53
9. Riccardi G, Giacco R, Parillo M, et al. Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: A placebo-controlled, double-blind, multicentre study. Diabet Med 1999;16(3):228-32
10. Sels JP, Verdonk HE, Wolffenbuttel BH. Effects of acarbose (Glucobay) in persons with type 1 diabetes: A multicentre study. Diabetes Res Clin Pract 1998;41(2):139-45
11. Neuser D, Benson A, Bruckner A, et al. Safety and tolerability of acarbose in the treatment of type 1 and type 2 diabetes mellitus. Clin Drug Investig 2005;25(9):579-87
12. Kubo S, Watada H, Kawamori R. Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients. J Diabetes Investig 2010;1(1-2):60-5
13. Taira M, Takasu N, Komiya I, et al. Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy. Metabolism 2000;49(4):440-3
14. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132(6):2131-57
15. Meier JJ. Beta cell mass in diabetes: A realistic therapeutic target? Diabetologia 2008;51(5):703-13
16. Pettus J, Hirsch I, Edelman S. GLP-1 agonists in type 1 diabetes. Clin Immunol 2013;149(3):317-23
17. Ellis SL, Moser EG, Snell-Bergeon JK, et al. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: A pilot, double-blind, randomized, crossover trial. Diabet Med 2011;28(10):1176-81
18. Kumar KVSH, Shaikh A, Prusty P. Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study. Diabetes Res Clin Pr 2013;100(2):E55-E8
19. Kutoh E. Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: A case series. J Med Case Rep 2011;5:117
20. Suarez-Pinzon WL, Power RF, Yan Y, et al. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 2008;57(12):3281-8
21. Griffin KJ, Thompson PA, Gottschalk M, et al. Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2014;2(9):710-18
22. Foley JE, Ligueros-Saylan M, He YL, et al. Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 2008;40(10):727-30
23. Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 2003;3(1):3
24. Kielgast U, Asmar M, Madsbad S, Holst JJ. Effect of glucagon-like peptide-1 on alpha-and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab 2010;95(5):2492-6
25. Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004;89(7):3469-73
26. Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges. Diabetes Care 2014;37(1):210-16
27. Raman VS, Mason KJ, Rodriguez LM, et al. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care 2010;33(6):1294-6
28. Rother KI, Spain LM, Wesley RA, et al. Effects of exenatide alone and in combination with daclizumab on betacell function in long-standing type 1 diabetes. Diabetes Care 2009;32(12):2251-7
29. Sarkar G, Alattar M, Brown RJ, et al. Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes. Diabetes Care 2014;37(3):666-70
30. Traina AN, Lull ME, Hui AC, et al. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy. Can J Diabetes 2014;38(4):269-72
31. Renukuntla VS, Ramchandani N, Trast J, et al. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm. J Diabetes Sci Technol 2014;8(5):1011-17
32. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011;34(7):1463-8
33. Varanasi A, Bellini N, Rawal D, et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 2011;165(1):77-84
34. Kuhadiya ND, Malik R, Bellini NJ, et al. Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus. Endocr Pract 2013;19(6):963-7
35. Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med 2013;61(1):40-4
36. Cariou B, Bernard C, Cantarovich D. Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series. Diabetes Metab 2014. [Epub ahead of print]
37. Leslie RD, Taylor R, Pozzilli P. The role of insulin resistance in the natural history of type 1 diabetes. Diabet Med 1997;14(4):327-31
38. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131(4):281-303
39. Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebocontrolled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003;149(4):323-9
40. Hamilton J, Cummings E, Zdravkovic V, et al. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: A randomized controlled trial. Diabetes Care 2003;26(1):138-43
41. Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS ONE 2008;3(10):e3363
42. Vella S, Buetow L, Royle P, et al. The use of metformin in type 1 diabetes: A systematic review of efficacy. Diabetologia 2010;53(5):809-20
43. Pitocco D, Zaccardi F, Tarzia P, et al. Metformin improves endothelial function in type 1 diabetic subjects: A pilot, placebo-controlled randomized study. Diabetes Obes Metab 2013;15(5):427-31
44. Codner E, Iniguez G, Lopez P, et al. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. Horm Res Paediatr 2013;80(5):343-9
45. Lund SS, Tarnow L, Astrup AS, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab 2009;11(10):966-77
46. Abdul-Ghani MA, DeFronzo RA. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. J Intern Med 2014;276(4):352-63
47. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose cotransporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 2014;23(6):875-82
48. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, doubleblind, placebo-controlled pilot study. Diabetes Care 2015;38(3):412-19
49. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014;37(5):1480-3
50. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28
51. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129(5):587-97
52. Cherney DZ, Perkins BA. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection? Can J Diabetes 2014;38(5):356-63
53. Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;jc20151884
54. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351(11):1106-18
55. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366(9493):1279-89
56. Bhat R, Bhansali A, Bhadada S, Sialy R. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract 2007;78(3):349-54
57. Zdravkovic V, Hamilton JK, Daneman D, Cummings EA. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr 2006;149(6):845-9
58. Tafuri KS, Godil MA, Lane AH, Wilson TA. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus. J Clin Res Pediatr Endocrinol 2013;5(4):236-9
59. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 2005;28(7):1562-7
60. Stone ML, Walker JL, Chisholm D, et al. The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: A randomized-controlled trial. Pediatr Diabetes 2008;9(4 Pt 1):326-34
61. Yang Z, Zhou Z, Li X, et al. Rosiglitazone preserves islet beta-cell function of adult-onset latent autoimmune diabetes in 3 years followup study. Diabetes Res Clin Pract 2009;83(1):54-60
62. Investigators F-ST. Design of FLATSUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. Diabetes Care 2015;38(8):1558-66
63. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 2013;12(2):153-75
64. Garg SK, Ritchie PJ, Moser EG, et al. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: A pilot randomized double-blind trial. Diabetes Obes Metab 2011;13(2):137-43
65. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124(2):509-14
66. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21(5):512-17